Aethlon Medical, Inc.

Good day and welcome to the Athlon Medical Fiscal Second Quarter 2025 Earnings and Corporate Update. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star and then two. Please note this event is being recorded. I would now like to turn the conference over to Michael Miller with Rx Communications. Please go ahead.

Thank you, operator, and good afternoon, everyone. Welcome to Athlon Medical's fiscal second quarter 2025 earnings conference call. My name is Michael Miller with Rx Communications. At 4.15 p.m. Eastern time today, Athlon Medical released financial results for its fiscal second quarter ended September 30th, 2024. If you have not seen or received Athlon Medical's earnings release, please visit the investors page at www.athlonmedical.com to view it. Following this introduction and the reading of the company's forward-looking statement disclaimer, Athlon's Chief Executive Officer and Chief Financial Officer, James Frakes, and Athlon's Chief Medical Officer, Dr. Stephen LaRosa, will provide an overview of Athlon's strategy and recent developments. Mr. Frakes will then make some brief remarks on Athlon's financials. We will then open up the call for the Q&A session. Before I hand the call over to Mr. Friggs, please note that the news released today and this call contain forward-looking statements within the meaning of the Securities Act of 1933 as amended and the Securities Exchange Act of 1934 as amended. The company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that could cause the results to differ materially from those anticipated in forward-looking statements can be found under the caption, Risk Factors, in the company's annual report on Form 10-K for the fiscal year ended March 31, 2024, the company's most recent quarterly report on Form 10-Q, and in the company's other filings with the Securities and Exchange Commission. Except as may be required by law, the company does not intend to, nor does it undertake any duty to update this information to reflect future events or circumstances. With that, I'll now turn the call over to Mr. James Frakes, Athlon's Chief Executive Officer and Chief Financial Officer. Jim.

Thank you, Mike. And I would like to thank all of you for dialing in. This is Jim Frakes. In October, as reported, Athlon's board of directors appointed me to serve as the company's permanent chief executive officer. I have served as interim CEO since November 2023, and I look forward to continuing my role on a permanent basis. As you know, Athlon Medical is continuing the research and clinical development of its hemopurifier, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the hemopurifier have important potential applications in oncology, where cancer-associated exosomes may promote immune suppression and metastasis, in life-threatening infectious diseases, and in organ transplantation. As a reminder, the two goals that I stated were our key objectives when I was appointed interim CEO were to move the company forward in oncology and to reduce our expenses in order to streamline operations. As you will hear shortly, and as I'm happy to note, we made measurable progress on both of these fronts during the latest quarter and into the current period. Specifically, our emphasis on expense reductions has allowed for optimized resource allocation. This in turn enabled our continued work on the high impact area of oncology I'm very pleased to say that we advanced our oncology trial efforts in Australia during the latest quarter and into the current period. I'm gratified by this progress and expect that our shareholders will ultimately be rewarded by our efforts. I will now turn the call over to Dr. La Rosa, who will give you an update on our oncology program to date, including one important milestone that we recently achieved and on other potential upcoming milestones we expect to report later this calendar year. Steve?